Neurooncology is the study of brain, spinal cord neoplasms and peripheral nerves.

Extent of resection is believed to be a key prognostic factor in neuro-oncology.

It remains a challenge in oncology to identify novel drug regimens to efficiently tackle glioblastoma, the most common primary brain tumor in adults.

Developments in modern oncological neurosurgery led to a shift from a strictly anatomic structural point of view to a more functional holistic model. Therefore, a distinctive and precise knowledge of the complexity of the brain and an integral three-dimensional idea of its structures are mandatory.

Transcranial focused ultrasound (FUS) can noninvasively transmit acoustic energy with a high degree of accuracy and safety to targets and regions within the brain. Technological advances, including phased-array transducers and real-time temperature monitoring with magnetic resonance thermometry, have created new opportunities for FUS research and clinical translation. Neurooncology, in particular, has become a major area of interest because FUS offers a multifaceted approach to the treatment of brain tumors. FUS has the potential to generate cytotoxicity within tumor tissue, both directly via thermal ablation and indirectly through radiosensitization and sonodynamic therapy; to enhance the delivery of therapeutic agents to brain tumors by transiently opening the blood-brain barrier or improving distribution through the brain extracellular space; and to modulate the tumor microenvironment to generate an immune response. In this review, we describe each of these applications for FUS, the proposed mechanisms of action, and the preclinical and clinical studies that have set the foundation for using FUS in neuro-oncology 1).


World Health Organization Classification of Tumors of the Central Nervous System


Journal of Neuro-Oncology

Neuro-Oncology Societies

Neuro-Oncology Guidelines

see Molecular neurooncology.

Research focus has shifted in the last decades towards the exploration of tumor infiltration by a variety of immune cells and their products. T cells, macrophages, B cells, and mast cells.

In neurooncology, the biology of neural stem cells (NSCs) has been pursued in two ways: as tumor initiating cells (TICs) and as a potential cell-based vehicle for gene therapy.

Neuro-Oncology: The Essentials

Neuro-Oncology: The Essentials, Third Edition, is a comprehensive introduction to the fundamental science and core clinical concepts behind the successful multidisciplinary management of patients with brain and spine tumors. Among the updates to this new edition are eight new chapter topics, including: Endoscopic Approaches, Pediatric Supratentorial Tumors, and Neuro-Oncology in the Developing World. The book begins with basic science, progresses to clinical applications, and includes a robust section on specific tumor types.

Key Features:

A major revision, with a 20% increase in content and over 35% increase in figures Editors Notes at the end of each chapter briefly summarize a topic, provide a historical perspective on a topic, add a current reference, or highlight salient points Demonstrates the latest surgical navigation techniques, including stereotaxy and intraoperative MRI, used to access hard-to-reach tumors This new edition is an invaluable reference for all neurosurgeons, neurologists, and oncologists, as well as residents and fellows, and it will be a treasured volume in their medical libraries for years to come.

Handbook of Neuro-Oncology Neuroimaging, Second Edition

Remarkable progress in neuro-oncology due to increased utilization of advanced imaging in clinical practice continues to accelerate in recent years. Refinements in magnetic resonance imaging (MRI) and computed tomography (CT) technology, and the addition of newer anatomical, functional, and metabolic imaging methods, such as MRS, fMRI, diffusion MRI, and DTI MRI have allowed brain tumor patients to be diagnosed much earlier and to be followed more carefully during treatment. With treatment approaches and the field of neuro-oncology neuroimaging changing rapidly, this second edition of the Handbook of Neuro-Oncology Neuroimaging is so relevant to those in the field, providing a single-source, comprehensive, reference handbook of the most up-to-date clinical and technical information regarding the application of neuro-Imaging techniques to brain tumor and neuro-oncology patients. This new volume will have updates on all of the material from the first edition, and in addition will feature several new important chapters covering diverse topics such as advanced imaging techniques in radiation therapy, therapeutic treatment fields, response assessment in clinical trials, surgical planning of neoplastic disease of the spine, and more. It will also serve as a resource of background information to neuroimaging researchers and basic scientists with an interest in brain tumors and neuro-oncology.

Provides a background to translational research and the use of brain imaging for brain tumors

Contains critical discussions on the potential and limitations of neuroimaging as a translational tool for the diagnosis and treatment of brain tumor and neuro-oncology patients

Presents an up-to-date reference on advanced imaging technologies, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), as well as the recent refinements in these techniques

Principles & Practice of Neuro-oncology: A Multidisciplinary Approach

Neuro-oncologic (brain and spine) cancers account for 19,000 new cases and 13,000 deaths per year. The early and proper diagnosis of these virulent cancers is critical to patient outcomes and diagnosis and treatment strategies are continually evolving. The multidisciplinary team that manages these patients involves medical radiation oncology, neurosurgery, molecular biology, neuroimaging, nurses and therapists. Principles and Practices of Neuro-Oncology establishes a new gold standard in care through a comprehensive, multidisciplinary text covering all aspects of neuro-oncology. Six major sections cover all topics related to epidemiology and etiology, clinical features and supportive care, imaging, neuroanatomy and neurosurgery, medical oncology and targeted therapies, and radiation oncology for adult and pediatric cancers. Expert contributors from multiple disciplines provide detailed and in-depth discussions of the the entire field of neuro-oncology including histopathologic harmonization, quality of life amd therapeutic changes in terms of combined modality treatments, the advent of new drugs, especially targeted agents, and the tantalizing early promise of personalized therapeutic approaches.

With contributions from over 180 authors, numerous diagrams, illustrations and tables, and a 48-page color plate section, Principles and Practice of Neuro-Oncology reflects the breadth and depth of this multi-faceted specialty.

Pediatric Neuro-oncology

“The editors…have done an outstanding job of presenting…complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners.” Amar Gajjar, MD in the Foreword

This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise.

Neuro-Oncology: Blue Books of Neurology Series

Neuro-Oncology-a new title in the Blue Books of Practical Neurology series-is a concise and clinically applicable guide to this dynamic subspecialty. Jeremy Rees, PhD, MRCP and Patrick Y. Wen, MD present the most current information on the treatment and management of primary CNS tumors, secondary brain tumors, and the neurological complications of other cancers and their therapies in a format and scope appealing to both the general neurologist and the subspecialist.

Access comprehensive coverage of treatment for adult and pediatric conditions-including tumors of the spinal cord as well as the brain.

Find coverage of recent advances easily thanks to the emphasis on the latest clinical and laboratory findings and their implications for clinical management and treatment.

Apply the possibilities and outcomes of neuro-oncologic surgery within the context of neurologic practice.

Address the neurologic complications of cancer and its treatment as well as of primary and secondary tumors.

Tap into the global perspectives of experts from all around the world for a multi-disciplinary approach to practice.

Neuro-Oncology Part I, Volume 104: Handbook of Clinical Neurology (Series Editors: Aminoff, Boller and Swaab)

Handbook of Clinical Neurology: Neuro-Oncology, Part I summarizes the present state of scientific and clinical knowledge in the field of neuro-oncology, including information related to diagnostic techniques such as imaging, along with immunology, molecular biology, and clinical aspects of tumors. Management and new therapeutic strategies for tumors, including gene therapy and molecularly targeted treatments, are also covered. Divided into eight sections encompassing 61 chapters, the book begins with an overview of the basic principles of tumors, including the epidemiology of primary central nervous system tumors, angiogenesis and invasion in cancer, the link between blood-brain barrier and brain edema, and the role of stem cells in gliomas. It proceeds with a discussion of diagnostic tools such as neuroimaging, the principles of tumor therapy such as radiotherapy and immunotherapy, and clinical trials in neuro-oncology. The reader is also introduced to specific tumor types such as low-grade gliomas, anaplastic astrocytomas, and medulloblastoma and primitive neuroectodermal tumors, along with rare brain tumors like neurofibromatosis and other genetic syndromes. Furthermore, the book explains the neurological complications of systemic cancer and complications from treatments. This volume will appeal to clinicians and neuroscientists as well as researchers who want to gain a better understanding of the clinical features and management of the neurological manifestations of tumors.

* An invaluable resource that includes critical, in-depth insights into recent developments in neuro-oncology

* A fresh perspective on molecular biology, immunology, and other clinical aspects of tumors of the nervous system

* Extensive coverage of tumor management and new therapeutic strategies, including gene therapy and molecularly targeted treatments

* New tactics and therapies that will aid clinicians in their quest to provide optimal care for their neuro-oncological patients

Country of Publication: England

Published monthly from January 2010, Neuro-Oncology is the official journal of the Society for NeuroOncology. Also affiliated with the Japan Society for Neuro-Oncology and the European Association for Neuro-Oncology it is a truly global journal in the field.

Dedicated to providing superior and rapid publication of information in all areas of neuro-oncology, the journal contains peer-reviewed articles and reviews, symposia on selected topics, published abstracts of annual meetings, and society news and announcements from around the world.

Nassiri F, Zadeh G, Aldape K. IDH mutation testing in gliomas-where do we draw the line? Neuro Oncol. 2017 Nov 29;19(12):1568-1569. doi: 10.1093/neuonc/nox164. PubMed PMID: 29140514; PubMed Central PMCID: PMC5716201.

4: Renfrow JJ, Weller M, Strowd RE. Meeting Update-World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017. Neuro Oncol. 2017 Oct 19;19(11):1457-1459. doi: 10.1093/neuonc/nox184. PubMed PMID: 29059448; PubMed Central PMCID: PMC5737526.

5: Couldwell WT, Cannon-Albright LA. A description of familial clustering of meningiomas in the Utah population. Neuro Oncol. 2017 Nov 29;19(12):1683-1687. doi: 10.1093/neuonc/nox127. PubMed PMID: 29016976; PubMed Central PMCID: PMC5716076.

6: Khagi S, Miller CR. Putting “multiforme” back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology. Neuro Oncol. 2017 Nov 29;19(12):1570-1571. doi: 10.1093/neuonc/nox131. PubMed PMID: 29016836; PubMed Central PMCID: PMC5716077.

7: Cavalheiro S. Intracystic interferon-alpha in pediatric craniopharyngioma patients. Neuro Oncol. 2017 Oct 1;19(10):1419. doi: 10.1093/neuonc/nox123. PubMed PMID: 28922862; PubMed Central PMCID: PMC5596168.

8: Zhang Z, Chan AK, Ding X, Li Y, Zhang R, Chen L, Liu Y, Wang Y, Xiong J, Ng HK, Yao Y, Zhou L. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro Oncol. 2017 Jul 1;19(7):1008-1010. doi: 10.1093/neuonc/nox042. PubMed PMID: 28874004; PubMed Central PMCID: PMC5570184.

9: Balasubramaniyan V, Bhat KP. Targeting MIR155HG in glioma: a novel approach. Neuro Oncol. 2017 Sep 1;19(9):1152-1153. doi: 10.1093/neuonc/nox095. PubMed PMID: 28821207; PubMed Central PMCID: PMC5570169.

10: Cooney T, Lane A, Bartels U, Bouffet E, Goldman S, Leary SES, Foreman NK, Packer RJ, Broniscer A, Minturn JE, Shih CS, Chintagumpala M, Hassall T, Gottardo NG, Dholaria H, Hoffman L, Chaney B, Baugh J, Doughman R, Leach JL, Jones BV, Fouladi M, Warren KE, Monje M. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 2017 Sep 1;19(9):1279-1280. doi: 10.1093/neuonc/nox107. PubMed PMID: 28821206; PubMed Central PMCID: PMC5570207.

11: Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, Preusser M, Le Rhun E, Vogelbaum MA, Zadeh G, Dhermain F, Weller M, Langen KJ, Tonn JC. PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol. 2017 Nov 29;19(12):1576-1587. doi: 10.1093/neuonc/nox112. Review. PubMed PMID: 28605532; PubMed Central PMCID: PMC5716194.

12: Morrow AM, Morgan RM, Villano JL. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials-impact of psychogenic non-epileptic seizures. Neuro Oncol. 2017 Jul 1;19(7):1010-1011. doi: 10.1093/neuonc/nox064. PubMed PMID: 28586447; PubMed Central PMCID: PMC5570171.

13: Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, Li KK, Chung NY, Yao Y, Zhou L, Wu J, Chen H, Ng HK. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol. 2017 Oct 1;19(10):1327-1337. doi: 10.1093/neuonc/nox078. PubMed PMID: 28575485; PubMed Central PMCID: PMC5596181.

14: Hachem LD, Mansouri A, Juraschka K, Taslimi S, Pirouzmand F, Zadeh G. Citation classics in neuro-oncology: assessment of historical trends and scientific progress. Neuro Oncol. 2017 Sep 1;19(9):1158-1172. doi: 10.1093/neuonc/nox053. PubMed PMID: 28531344; PubMed Central PMCID: PMC5570246.

15: Karimi S, Vyas MV, Gonen L, Tabasinejad R, Ostrom QT, Barnholtz-Sloan J, Suppiah S, Zadeh G, Aldape K. Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. Neuro Oncol. 2017 Oct 19;19(11):1503-1510. doi: 10.1093/neuonc/nox089. PubMed PMID: 28531342; PubMed Central PMCID: PMC5737603.

16: Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054. PubMed PMID: 28531337; PubMed Central PMCID: PMC5737620.

17: Colman H. Toward more informative biomarker-based clinical trials in glioblastoma. Neuro Oncol. 2017 Jul 1;19(7):880-881. doi: 10.1093/neuonc/nox063. PubMed PMID: 28521009; PubMed Central PMCID: PMC5570242.

18: Griesinger AM, Witt DA, Grob ST, Georgio Westover SR, Donson AM, Sanford B, Mulcahy Levy JM, Wong R, Moreira DC, DeSisto JA, Balakrishnan I, Hoffman LM, Handler MH, Jones KL, Vibhakar R, Venkataraman S, Foreman NK. NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. Neuro Oncol. 2017 Oct 1;19(10):1350-1360. doi: 10.1093/neuonc/nox061. PubMed PMID: 28510691; PubMed Central PMCID: PMC5596179.

19: Kilday JP, Caldarelli M, Massimi L, Chen RH, Lee YY, Liang ML, Parkes J, Naiker T, van Veelen ML, Michiels E, Mallucci C, Pettorini B, Meijer L, Dorfer C, Czech T, Diezi M, Schouten-van Meeteren AYN, Holm S, Gustavsson B, Benesch M, Müller HL, Hoffmann A, Rutkowski S, Flitsch J, Escherich G, Grotzer M, Spoudeas HA, Azquikina K, Capra M, Jiménez-Guerra R, MacDonald P, Johnston DL, Dvir R, Constantini S, Kuo MF, Yang SH, Bartels U. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol. 2017 Oct 1;19(10):1398-1407. doi: 10.1093/neuonc/nox056. PubMed PMID: 28499018; PubMed Central PMCID: PMC5596165.

20: Yesilöz Ü, Kirches E, Hartmann C, Scholz J, Kropf S, Sahm F, Nakamura M, Mawrin C. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro Oncol. 2017 Aug 1;19(8):1088-1096. doi: 10.1093/neuonc/nox018. PubMed PMID: 28482067; PubMed Central PMCID: PMC5570238.

21: Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017 Oct 19;19(11):1447-1456. doi: 10.1093/neuonc/nox094. Review. PubMed PMID: 28482042; PubMed Central PMCID: PMC5737364.

22: Schmidt C, Schubert NA, Brabetz S, Mack N, Schwalm B, Chan JA, Selt F, Herold-Mende C, Witt O, Milde T, Pfister SM, Korshunov A, Kool M. Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro Oncol. 2017 Nov 29;19(12):1607-1617. doi: 10.1093/neuonc/nox093. PubMed PMID: 28482026; PubMed Central PMCID: PMC5716199.

23: Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ. Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. Neuro Oncol. 2017 Oct 1;19(10):1391-1397. doi: 10.1093/neuonc/nox090. PubMed PMID: 28472527; PubMed Central PMCID: PMC5596170.

24: Figueroa JM, Skog J, Akers J, Li H, Komotar R, Jensen R, Ringel F, Yang I, Kalkanis S, Thompson R, LoGuidice L, Berghoff E, Parsa A, Liau L, Curry W, Cahill D, Bettegowda C, Lang FF, Chiocca EA, Henson J, Kim R, Breakefield X, Chen C, Messer K, Hochberg F, Carter BS. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017 Oct 19;19(11):1494-1502. doi: 10.1093/neuonc/nox085. PubMed PMID: 28453784; PubMed Central PMCID: PMC5737576.

25: Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review. PubMed PMID: 28453751; PubMed Central PMCID: PMC5464449.

26: Terrier LM, Bauchet L, Rigau V, Amelot A, Zouaoui S, Filipiak I, Caille A, Almairac F, Aubriot-Lorton MH, Bergemer-Fouquet AM, Bord E, Cornu P, Czorny A, Dam Hieu P, Debono B, Delisle MB, Emery E, Farah W, Gauchotte G, Godfraind C, Guyotat J, Irthum B, Janot K, Le Reste PJ, Liguoro D, Loiseau H, Lot G, Lubrano V, Mandonnet E, Menei P, Metellus P, Milin S, Muckenstrum B, Roche PH, Rousseau A, Uro-Coste E, Vital A, Voirin J, Wager M, Zanello M, François P, Velut S, Varlet P, Figarella-Branger D, Pallud J, Zemmoura I; Club de Neuro-Oncologie of the Société Française de Neurochirurgie. Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. Neuro Oncol. 2017 May 1;19(5):678-688. doi: 10.1093/neuonc/now186. PubMed PMID: 28453747; PubMed Central PMCID: PMC5464461.

27: Zhu C, Mustafa D, Zheng PP, van der Weiden M, Sacchetti A, Brandt M, Chrifi I, Tempel D, Leenen PJM, Duncker DJ, Cheng C, Kros JM. Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression. Neuro Oncol. 2017 May 1;19(5):648-659. doi: 10.1093/neuonc/now251. PubMed PMID: 28453746; PubMed Central PMCID: PMC5464467.

28: Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017 May 1;19(5):660-668. doi: 10.1093/neuonc/now239. PubMed PMID: 28453745; PubMed Central PMCID: PMC5464439.

29: Han YP, Enomoto A, Shiraki Y, Wang SQ, Wang X, Toyokuni S, Asai N, Ushida K, Ara H, Ohka F, Wakabayashi T, Ma J, Natsume A, Takahashi M. Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells. Neuro Oncol. 2017 May 1;19(5):636-647. doi: 10.1093/neuonc/now237. PubMed PMID: 28453744; PubMed Central PMCID: PMC5464440.

30: Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077. PubMed PMID: 28444227; PubMed Central PMCID: PMC5737512.

31: Brokinkel B, Hess K, Mawrin C. Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review. Neuro Oncol. 2017 Oct 1;19(10):1298-1307. doi: 10.1093/neuonc/nox071. Review. PubMed PMID: 28419308; PubMed Central PMCID: PMC5596167.

32: Weil S, Osswald M, Solecki G, Grosch J, Jung E, Lemke D, Ratliff M, Hänggi D, Wick W, Winkler F. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro Oncol. 2017 Oct 1;19(10):1316-1326. doi: 10.1093/neuonc/nox070. PubMed PMID: 28419303; PubMed Central PMCID: PMC5596180.

33: Alvarez-Breckenridge C, Brastianos PK. SMO mutant olfactory groove meningiomas-the next in line for targeted therapy. Neuro Oncol. 2017 Mar 1;19(3):305-306. doi: 10.1093/neuonc/now302. PubMed PMID: 28391317; PubMed Central PMCID: PMC5464315.

34: Jenkinson MD, Santarius T, Zadeh G, Aldape KD. Atypical meningioma-is it time to standardize surgical sampling techniques? Neuro Oncol. 2017 Mar 1;19(3):453-454. doi: 10.1093/neuonc/now245. PubMed PMID: 28391316; PubMed Central PMCID: PMC5464334.

35: Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Rudà R, Tonn JC, Weber DC, Weller M. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017 Feb 1;19(2):162-174. doi: 10.1093/neuonc/now241. PubMed PMID: 28391295; PubMed Central PMCID: PMC5620494.

36: Wen PY, Jiang T, Schiff D. How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies. Neuro Oncol. 2017 Apr 1;19(4):459-460. doi: 10.1093/neuonc/nox041. PubMed PMID: 28388714; PubMed Central PMCID: PMC5464309.

37: Brennan C. FGFR-TACC approaches the first turn in the race for targetable GBM mutations. Neuro Oncol. 2017 Apr 1;19(4):461-462. doi: 10.1093/neuonc/nox005. PubMed PMID: 28388710; PubMed Central PMCID: PMC5464322.

38: Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, Takahashi M, Matsumoto H, Hacke K, Kruse CA, Ostertag D, Robbins JM, Gruber HE, Jolly DJ, Kasahara N. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol. 2017 Jul 1;19(7):918-929. doi: 10.1093/neuonc/nox038. PubMed PMID: 28387831; PubMed Central PMCID: PMC5574670.

39: Sahgal A, Ruschin M, Ma L, Verbakel W, Larson D, Brown PD. Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues. Neuro Oncol. 2017 Apr 1;19(suppl_2):ii2-ii15. doi: 10.1093/neuonc/nox001. Review. PubMed PMID: 28380635; PubMed Central PMCID: PMC5463499.

40: Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD. The radiosurgery fractionation quandary: single fraction or hypofractionation? Neuro Oncol. 2017 Apr 1;19(suppl_2):ii38-ii49. doi: 10.1093/neuonc/now301. PubMed PMID: 28380634; PubMed Central PMCID: PMC5463582.

41: Thompson EM, Keir ST, Venkatraman T, Lascola C, Yeom KW, Nixon AB, Liu Y, Picard D, Remke M, Bigner DD, Ramaswamy V, Taylor MD. The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. Neuro Oncol. 2017 Sep 1;19(9):1217-1227. doi: 10.1093/neuonc/nox033. PubMed PMID: 28379574; PubMed Central PMCID: PMC5570262.

42: Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvuori P, Yli-Harja O, Visakorpi T, Haapasalo H, Nykter M, Zhang W. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro Oncol. 2017 Sep 1;19(9):1206-1216. doi: 10.1093/neuonc/nox028. PubMed PMID: 28379477; PubMed Central PMCID: PMC5570261.

43: Lawler SE. Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. Neuro Oncol. 2017 Apr 1;19(4):463-465. doi: 10.1093/neuonc/nox011. PubMed PMID: 28379450; PubMed Central PMCID: PMC5464378.

44: Takayanagi S, Mukasa A, Tanaka S, Nomura M, Omata M, Yanagisawa S, Yamamoto S, Ichimura K, Nakatomi H, Ueki K, Aburatani H, Saito N. Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system. Neuro Oncol. 2017 Sep 1;19(9):1228-1236. doi: 10.1093/neuonc/nox034. PubMed PMID: 28379443; PubMed Central PMCID: PMC5570160.

45: Russell L, Bolyard C, Banasavadi-Siddegowda Y, Weiss A, Zhang J, Shakya R, Powell K, Kaur B. Sex as a biological variable in response to temozolomide. Neuro Oncol. 2017 Jun 1;19(6):873-874. doi: 10.1093/neuonc/nox040. PubMed PMID: 28379437; PubMed Central PMCID: PMC5464457.

46: Wu X, Wang Y, Yu T, Nie E, Hu Q, Wu W, Zhi T, Jiang K, Wang X, Lu X, Li H, Liu N, Zhang J, You Y. Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017 Sep 1;19(9):1195-1205. doi: 10.1093/neuonc/nox017. PubMed PMID: 28371892; PubMed Central PMCID: PMC5570208.

47: Wang C, Kaprealian TB, Suh JH, Kubicky CD, Ciporen JN, Chen Y, Jaboin JJ. Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. Neuro Oncol. 2017 Sep 1;19(9):1263-1270. doi: 10.1093/neuonc/nox007. PubMed PMID: 28371851; PubMed Central PMCID: PMC5570224.

48: Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026. PubMed PMID: 28371827; PubMed Central PMCID: PMC5570198.

49: Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, Araki A, Brandstetter A, Mohr T, Hovestadt V, Chavez L, Kirchhofer D, Ricken G, Stefanits H, Korshunov A, Pfister SM, Dieckmann K, Azizi AA, Czech T, Filipits M, Kool M, Peyrl A, Slavc I, Berger W, Haberler C. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro Oncol. 2017 Sep 1;19(9):1183-1194. doi: 10.1093/neuonc/nox027. PubMed PMID: 28371821; PubMed Central PMCID: PMC5570194.

50: Lee YE, Choi SA, Kwack PA, Kim HJ, Kim IH, Wang KC, Phi JH, Lee JY, Chong S, Park SH, Park KD, Hwang DW, Joo KM, Kim SK. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor. Neuro Oncol. 2017 Aug 1;19(8):1079-1087. doi: 10.1093/neuonc/now300. PubMed PMID: 28340172; PubMed Central PMCID: PMC5570172.

51: Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285. PubMed PMID: 28340142; PubMed Central PMCID: PMC5464432.

52: Mei X, Chen YS, Chen FR, Xi SY, Chen ZP. Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. Neuro Oncol. 2017 Aug 1;19(8):1109-1118. doi: 10.1093/neuonc/nox016. PubMed PMID: 28340100; PubMed Central PMCID: PMC5570159.

53: Cheng W, Zhang C, Ren X, Wang Z, Liu X, Han S, Wu A. Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. Neuro Oncol. 2017 May 1;19(5):736-738. doi: 10.1093/neuonc/nox012. PubMed PMID: 28339964; PubMed Central PMCID: PMC5464430.

54: Cote DJ, Downer MK, Zoltick ES, Smith TR, Stampfer MJ. ABO blood group and risk of glioma. Neuro Oncol. 2017 Jun 1;19(6):871-873. doi: 10.1093/neuonc/nox013. PubMed PMID: 28339823; PubMed Central PMCID: PMC5464450.

55: Wefel JS, Noll KR, Rao G, Cahill DP. Reply to Freyschlag et al. Neuro Oncol. 2017 Apr 1;19(4):598-599. doi: 10.1093/neuonc/now296. PubMed PMID: 28339696; PubMed Central PMCID: PMC5464303.

56: Freyschlag CF, Kerschbaumer J, Thomé C. Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol. 2017 Apr 1;19(4):597-598. doi: 10.1093/neuonc/now289. PubMed PMID: 28339651; PubMed Central PMCID: PMC5464311.

57: D'Alessandris QG, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T, Signore M, Stancato L, Olivi A, De Maria R, Larocca LM, Ricci-Vitiani L, Pallini R. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro Oncol. 2017 Aug 1;19(8):1097-1108. doi: 10.1093/neuonc/now304. PubMed PMID: 28204560; PubMed Central PMCID: PMC5737323.

58: Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT Jr, Cahill DP, Barker FG 2nd, Brastianos PK, Santagata S. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 Apr 1;19(4):535-545. doi: 10.1093/neuonc/now235. PubMed PMID: 28170043; PubMed Central PMCID: PMC5464371.

59: Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287. PubMed PMID: 28115578; PubMed Central PMCID: PMC5464463.

60: Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O'Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE, Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM, Chi SN, Beroukhim R, Ligon KL. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 1;19(7):986-996. doi: 10.1093/neuonc/now294. PubMed PMID: 28104717; PubMed Central PMCID: PMC5570190.

61: Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M. Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score. Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290. PubMed PMID: 28096493; PubMed Central PMCID: PMC5570252.

62: Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA, Stiles CD. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 Jun 1;19(6):774-785. doi: 10.1093/neuonc/now261. PubMed PMID: 28082416; PubMed Central PMCID: PMC5464455.

63: Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro Oncol. 2017 Mar 1;19(3):345-351. doi: 10.1093/neuonc/now276. PubMed PMID: 28082415; PubMed Central PMCID: PMC5464306.

64: Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol. 2017 Jun 1;19(6):820-832. doi: 10.1093/neuonc/now253. PubMed PMID: 28062830; PubMed Central PMCID: PMC5464448.

65: Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA. The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study. Neuro Oncol. 2017 Jul 1;19(7):976-985. doi: 10.1093/neuonc/now272. PubMed PMID: 28040713; PubMed Central PMCID: PMC5570185.

66: Tscherpel C, Dunkl V, Ceccon G, Stoffels G, Judov N, Rapp M, Meyer PT, Kops ER, Ermert J, Fink GR, Shah NJ, Langen KJ, Galldiks N. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. Neuro Oncol. 2017 May 1;19(5):710-718. doi: 10.1093/neuonc/now243. PubMed PMID: 28039366; PubMed Central PMCID: PMC5464428.

67: Zamanipoor Najafabadi AH, Peeters MCM, Dirven L, Lobatto DJ, Groen JL, Broekman MLD, Peerdeman SM, Peul WC, Taphoorn MJB, van Furth WR. Impaired health-related quality of life in meningioma patients-a systematic review. Neuro Oncol. 2017 Jul 1;19(7):897-907. doi: 10.1093/neuonc/now250. Review. PubMed PMID: 28039363; PubMed Central PMCID: PMC5570251.

68: Yang W, Garzon-Muvdi T, Braileanu M, Porras JL, Caplan JM, Rong X, Huang J, Jallo GI. Primary intramedullary spinal cord lymphoma: a population-based study. Neuro Oncol. 2017 Mar 1;19(3):414-421. doi: 10.1093/neuonc/now178. PubMed PMID: 28011925; PubMed Central PMCID: PMC5464325.

69: Liu TT, Achrol AS, Mitchell LA, Rodriguez SA, Feroze A, Iv M, Kim C, Chaudhary N, Gevaert O, Stuart JM, Harsh GR, Chang SD, Rubin DL. Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro Oncol. 2017 Jul 1;19(7):997-1007. doi: 10.1093/neuonc/now270. PubMed PMID: 28007759; PubMed Central PMCID: PMC5570189.

70: Lee J, Hoxha E, Song HR. A novel NFIA-NFκB feed-forward loop contributes to glioblastoma cell survival. Neuro Oncol. 2017 Apr 1;19(4):524-534. doi: 10.1093/neuonc/now233. PubMed PMID: 27994064; PubMed Central PMCID: PMC5473440.

71: Peng S, Dhruv H, Armstrong B, Salhia B, Legendre C, Kiefer J, Parks J, Virk S, Sloan AE, Ostrom QT, Barnholtz-Sloan JS, Tran NL, Berens ME. Integrated genomic analysis of survival outliers in glioblastoma. Neuro Oncol. 2017 Jun 1;19(6):833-844. doi: 10.1093/neuonc/now269. PubMed PMID: 27932423; PubMed Central PMCID: PMC5464466.

72: Yang L, He K, Yan S, Yang Y, Gao X, Zhang M, Xia Z, Huang Z, Huang S, Zhang N. Metadherin/Astrocyte elevated gene-1 positively regulates the stability and function of forkhead box M1 during tumorigenesis. Neuro Oncol. 2017 Mar 1;19(3):352-363. doi: 10.1093/neuonc/now229. PubMed PMID: 27923917; PubMed Central PMCID: PMC5464332.

73: Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger AB. Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. 2017 Mar 1;19(3):372-382. doi: 10.1093/neuonc/now198. PubMed PMID: 27765835; PubMed Central PMCID: PMC5464307.

74: Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017 Jun 1;19(6):750-761. doi: 10.1093/neuonc/now209. Review. PubMed PMID: 27683733; PubMed Central PMCID: PMC5464436.

75: Bettegowda C, Yip S, Lo SL, Fisher CG, Boriani S, Rhines LD, Wang JY, Lazary A, Gambarotti M, Wang WL, Luzzati A, Dekutoski MB, Bilsky MH, Chou D, Fehlings MG, McCarthy EF, Quraishi NA, Reynolds JJ, Sciubba DM, Williams RP, Wolinsky JP, Zadnik PL, Zhang M, Germscheid NM, Kalampoki V, Varga PP, Gokaslan ZL; AOSpine Knowledge Forum Tumor. Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. Neuro Oncol. 2017 Mar 1;19(3):405-413. doi: 10.1093/neuonc/now156. PubMed PMID: 27663388; PubMed Central PMCID: PMC5464366.

76: Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2017 Jan;19(1):12-21. doi: 10.1093/neuonc/now190. Epub 2016 Sep 20. Review. PubMed PMID: 27651472; PubMed Central PMCID: PMC5193028.

77: Wagner S, Lanfermann H, Eichner G, Gufler H. Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI. Neuro Oncol. 2017 Apr 1;19(4):586-594. doi: 10.1093/neuonc/now193. PubMed PMID: 27634933; PubMed Central PMCID: PMC5464319.

78: Kim EH, Lee JH, Oh Y, Koh I, Shim JK, Park J, Choi J, Yun M, Jeon JY, Huh YM, Chang JH, Kim SH, Kim KS, Cheong JH, Kim P, Kang SG. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. Neuro Oncol. 2017 Feb 1;19(2):197-207. doi: 10.1093/neuonc/now174. PubMed PMID: 27571886; PubMed Central PMCID: PMC5464255.

79: Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 Feb 1;19(2):242-251. doi: 10.1093/neuonc/now176. PubMed PMID: 27571885; PubMed Central PMCID: PMC5464133.

80: McTyre ER, Johnson AG, Ruiz J, Isom S, Lucas JT Jr, Hinson WH, Watabe K, Laxton AW, Tatter SB, Chan MD. Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. Neuro Oncol. 2017 Apr 1;19(4):558-566. doi: 10.1093/neuonc/now184. PubMed PMID: 27571883; PubMed Central PMCID: PMC5464318.

81: Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol. 2017 Mar 1;19(3):394-404. doi: 10.1093/neuonc/now189. PubMed PMID: 27571882; PubMed Central PMCID: PMC5464302.

82: Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins RB, Sicotte H, Kollmeyer TM, O'Neill BP, Elmquist W, Hoxworth JM, Frakes D, Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol. 2017 Jan;19(1):128-137. doi: 10.1093/neuonc/now135. Epub 2016 Aug 8. PubMed PMID: 27502248; PubMed Central PMCID: PMC5193022.

83: Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol. 2017 Jan;19(1):55-65. doi: 10.1093/neuonc/now129. Epub 2016 Jul 28. PubMed PMID: 27471108; PubMed Central PMCID: PMC5193021.

84: Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, Bauer E, Hamisch C, Ruge MI, Kocher M, Kuchelmeister K, Sellhaus B, Sabel M, Fink GR, Shah NJ, Langen KJ, Galldiks N. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol. 2017 Feb 1;19(2):281-288. doi: 10.1093/neuonc/now149. PubMed PMID: 27471107; PubMed Central PMCID: PMC5463967.

85: Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E, Berendsen S, Dedobbeleer M, Willems E, Robe P, Bours V, Martin D, Martinive P, Maquet P, Rogister B. CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol. 2017 Jan;19(1):66-77. doi: 10.1093/neuonc/now136. Epub 2016 Jul 1. PubMed PMID: 27370398; PubMed Central PMCID: PMC5193023.

86: Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 Jan;19(1):109-117. doi: 10.1093/neuonc/now121. Epub 2016 Jun 26. PubMed PMID: 27353503; PubMed Central PMCID: PMC5193019.

87: Bentley RT, Ahmed AU, Yanke AB, Cohen-Gadol AA, Dey M. Dogs are man's best friend: in sickness and in health. Neuro Oncol. 2017 Mar 1;19(3):312-322. doi: 10.1093/neuonc/now109. Review. PubMed PMID: 27298310; PubMed Central PMCID: PMC5464314.

Hersh DS, Kim AJ, Winkles JA, Eisenberg HM, Woodworth GF, Frenkel V. Emerging Applications of Therapeutic Ultrasound in Neuro-oncology: Moving Beyond Tumor Ablation. Neurosurgery. 2016 Aug 22. [Epub ahead of print] PubMed PMID: 27552589.
  • neuro-oncology.txt
  • Last modified: 2022/05/13 12:55
  • by administrador